Oral Teriflunomide study shows lasting efficacy and safety
Oral Teriflunomide study shows lasting efficacy and safety
The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.
The findings came from open-label extensions of phase II and III studies with teriflunomide, which is now under FDA review as a treatment for relapsing-remitting MS. The results were presented in a series of posters at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1923 Views
-
Last post by NHE
-
- 0 Replies
- 1227 Views
-
Last post by frodo
-
- 0 Replies
- 901 Views
-
Last post by frodo
-
- 0 Replies
- 8645 Views
-
Last post by NHE
-
- 0 Replies
- 1579 Views
-
Last post by Tif
-
- 0 Replies
- 1366 Views
-
Last post by NHE
-
- 1 Replies
- 1031 Views
-
Last post by Petr75
-
- 0 Replies
- 1636 Views
-
Last post by DIM
-
- 0 Replies
- 1855 Views
-
Last post by DIM